Table4.

Clinical trials of CD47 BsAb in solid tumors

BsAb	IgG subclass	Target	Conditions	Monotherapy or Combination	Number of patients recruited	Phases stage	Clinical trial NO
HX009	IgG4	CD47 +  PD-1	Advanced solid tumor	Monotherapy	21 participants	Phase I	NCT04097769
			Advanced solid tumor	Monotherapy	210 participants	Phase II	NCT04886271
IBI322		CD47 +  PD-L1	Advanced solid tumor	Monotherapy	36 participants	Phase I	NCT04912466
			Advanced malignant tumors lymphomas	Monotherapy	51 participants	Phase I	NCT04338659
			Advanced malignancies	Monotherapy	218 participants	Phase I	NCT04328831
			Small cell lung cancer	Combination	40 participants	Phase II	NCT05296603
			Non small cell lung cancer	Combination	80 participants	Phase II	NCT05296278
			Myeloid tumor	Combination	124 participants	Phase I	NCT05148442
6MW3211		CD47 +  PD-L1	Advanced malignant neoplasm	Monotherapy	272 participants	Phase I/II	NCT05048160
PF-07257876	IgG1	CD47 +  PD-L1	NSCLC SCCHN and ovarian cancer	Monotherapy	90 participants	Phase I	NCT04881045
IBC0966		CD47 +  PD-L1	Advanced malignant tumors	Monotherapy	228 participants	Phase I/II	NCT04980690
IMM2902	IgG1	CD47 +  HER2	HER2 + advanced solid tumors	Monotherapy	40 participants	Phase I	NCT05076591